LIVERFASt™, is Non-invasive panel driven AI technology by combining 10 biological markers with patients’ characteristics of interest (age, gender, and BMI).

Calculates three quantitative scores between 0.00 and 1.00 that correlate to the NAFLD histopathology staging and grading of fibrosis, activity, and steatosis, respectively.

Covers the entire spectrum of the disease from early to late stages, including differentiating the severity of cirrhosis.

The test uniquely combines the ease of use and clinical sensitivity needed to do the large-scale testing which is crucial for the effective identification and monitoring of a high prevalence condition such as *MAFLD/MASH.